- Home
- BTAI vs GROW Comparison
BTAI vs GROW Comparison
Compare BTAI & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTAI | GROW |
|---|---|---|
| Founded | 2017 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 31.3M |
| IPO Year | 2018 | 1995 |
Fundamental Metrics
Financial Performance| Metric | BTAI | GROW |
|---|---|---|
| Price | $1.22 | $2.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 735.8K | 18.0K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 3.53% |
| EPS Growth | ★ 75.63 | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $23,850,609.00 |
| Revenue This Year | $197.82 | N/A |
| Revenue Next Year | $910.15 | N/A |
| P/E Ratio | ★ N/A | $9.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $2.16 |
| 52 Week High | $8.08 | $3.65 |
Technical Indicators
Market Signals| Indicator | BTAI | GROW |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 47.82 |
| Support Level | $1.02 | $2.33 |
| Resistance Level | $1.26 | $2.73 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 55.71 | 38.79 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.